Transaction #37236 · Form 4 · 0002095703-26-000008
Minerva Neurosciences, Inc. · Stock award · Stock Option (right to buy)
Minerva Neurosciences, Inc. · Transacted November 2, 2026 · Filed November 3, 2026
What does this filing report?
An SEC Form 4 filing for Minerva Neurosciences, Inc. records a stock award involving Stock Option (right to buy) on November 2, 2026. The reported quantity was 2,328. The filing date is November 3, 2026. This is one transaction record; amounts are not allocated among any joint reporting owners.
The acquisition category describes how securities were received. It does not by itself establish a cash purchase of common stock. Read the transaction code definitionsand the original filing before interpreting the amounts.
Transaction details
- Company
- Minerva Neurosciences, Inc.
- Company CIK
- 0001598646
- Security type
- Derivative
- Acquisition type
- Stock award · Code A
- Quantity acquired
- 2,328
- Reported price
- 0
- Reference value
- 0
- Currency
- Currency not specified
- Ownership
- Direct
- Holdings after transaction
- 2,328
- Ownership description
- Not reported
- SEC acceptance time
- Nov 3, 2026, 6:05 PM EST
- 10b5-1 indication
- Not indicated
Reference value is reported quantity × reported price. It is not a confirmed cash payment or an estimate of a derivative's economic value. A missing currency is not assumed to be USD.
Reporting owners
- Kaul Inderjit ↗
Director
CIK 0002095703
These are the reporting owners named in the filing. Quantities and amounts are not allocated among co-reporters. Roles reflect this filing, not a current profile.
Company listings
This transaction is not mapped to a specific company listing.
Derivative terms
- Underlying security
- Common Stock
- Underlying quantity
- 2,328
- Conversion / exercise price
- 2.345
- Exercise date
- Not reported
- Expiration date
- November 2, 2036
Filing footnotes & remarks
- F1
- 25% of the option shall vest on November 14, 2026; an additional 45% of the Consultant Option shall vest on the tenth day following the date of the Company's public announcement that it has achieved, on a statistically significant basis, the primary endpoint of its Phase 3 confirmatory trial of roluperidone in schizophrenia at the 12-week timepoint; and the remaining 30% of the Consultant Option shall vest on the tenth day following the date of the Company's public announcement of safety data from the 40-week relapse assessment phase; provided, however, in each case, that the Reporting Person is providing services pursuant to that certain consulting agreement dated November 14, 2025 on each such vesting date.
Footnotes are reproduced as plain text from the current source filing. For the full context, read the original SEC filing.
This record was updated Eastern Time. This is the stored record update time, not the transaction date. Report a correction.